ENVB Stock Forecast: Enveric Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.35
−4.26% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$6.3M
Ticker Nerd rank
16/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$2.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.9%
1M
−6.2%
YTD
−62.8%
1Y
−76.9%
From 52W high
−86.9%
From 52W low
+6.3%
$1
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Enveric Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
16/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
63
Volatility
51
Accruals
49
Revisions
20
Issuance
20
Value
18
Quality
15
Momentum
6

Growth (63): Sales and profits are climbing, and climbing faster than before.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENVB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENVB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1$2$3$4$5$6$7Jan 26Apr 26Jul 26Oct 26ENVB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Mar 2025HC Wainwright & Co.ReiteratesBuy$10
30 Jan 2024HC Wainwright & Co.InitiatesBuy—
1 June 2022Alliance Global PartnersInitiatesBuy$1.25
8 Mar 2022Aegis CapitalDowngradeHold$7.00 → $0.20
8 July 2021Aegis CapitalInitiatesBuy—
28 June 2021Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ENVB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ENVB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Enveric Biosciences, Inc. returned −76.9% against +6.9% for the S&P 500, dividends included.

ENVB vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ENVBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENVB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.4×

Cheaper than 90% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−170.0%

Higher than 8% of US stocks

Return on assets
−87.3%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enveric Biosciences, Inc. has a market value of $6.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 3.9M.

  • Enveric Biosciences, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ENVB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENVBEnveric Biosciences, Inc.$6.3M16
GTBPGT Biopharma, Inc.$6.1M13
CNSYCerenome, Inc.$6.2M13
OPHICollPlant Biotechnologies Ltd.$5.9M28
ACXPAcurx Pharmaceuticals, Inc.$6.3M18
KYNBKyntra Bio, Inc.$6.3M41
FBLGFibroBiologics, Inc.$6.3M64

Take a look at ENVB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Enveric Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ENVB

How does Ticker Nerd's model rank ENVB?

As at 21 Nov 2026, Enveric Biosciences, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (63 of 100).

What is the ENVB stock forecast for 2030?

No analyst covering Enveric Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENVB are extrapolating price history, which says nothing about the business.

How has ENVB stock performed over the past year?

Enveric Biosciences, Inc. returned -76.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enveric Biosciences, Inc. do?

Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions.

Company

About Enveric Biosciences, Inc.

Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.

CEO Dr. Joseph Edward Tucker Ph.D. · 5 employees · United States · https://www.enveric.com